As an organization led by Phelan-McDermid syndrome parents, we know that our movement wouldn't be here without the love, hope, and drive of PMS caregivers and advocates. This month, we're proud to offer multiple opportunities for caregivers and advocates to share their insights and to celebrate their loved ones.

In this issue, our CSO Ralf Schmid shares highlights from the 2026 ASGCT Annual Meeting, where gene therapy for brain diseases made major strides. We're also celebrating the launch of the Start Genetic Community Newsletter, spotlighting Genetic Testing Action Day on July 25th, and featuring new research participation opportunities, including the PMS Caregiver Milestone Study.

CureSHANK’s 3rd annual Phelan-McDermid Syndrome Drug Development Symposium brought together researchers, clinicians, industry leaders, and families for two days of remarkable science, community, and hope. Read on for key takeaways and insights that will shape the future of PMS drug development.